WATERTOWN, Mass. — Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced early proof-of-concept data for its first-in-class sialidase-Fc fusion protein HLX79/E-602 (efgitasialase alfa) in primary membranous nephropathy (pMN). The results were presented in an oral session at the American College of...

SAN DIEGO, Calif. — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, announced today that it has entered into a clinical supply agreement with Coherus Oncology, Inc. (“Coherus”) to evaluate Oncolytics’ investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus’ next-generation PD-1 inhibitor, LOQTORZI®...

Tokyo,Japan – Daiichi Sankyo (TSE: 4568) has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu® (trastuzumab deruxtecan) for the treatment of patients with HER2 expressing (immunohistochemistry [IHC] 3+, IHC 2+ or IHC 1+) advanced or recurrent uterine carcinosarcoma. Enhertu is...